Biotech News

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix (OCUL)Ocular TherapeutixCommercial

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company’s new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Related news

Ocular Therapeutix

Sustained Ocular Drug Delivery Ocular Therapeutix develops bioresorbable hydrogel implants designed to deliver drugs within the eye for extended periods. Its lead franchise seeks to reduce the frequency of anti-VEGF injections for retinal vascular diseases. AXPAXLI AXPAXLI is an intravitreal hydrogel implant containing axitinib, a...

Recent company news

Stock data

Close
5.86 USD
Market cap
1.82B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States